Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve Chan

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2012
Variation in telangiectasia predisposing genes is associated with overall radiation toxicityGeorge A Tanteles, Robert J S Murray, Jamie Mills, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2015
SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast CancerWilbert Zwart, Koen D Flach, Bharath Rudraraju, et al.
Breast Cancer Research and Treatment|August 22, 2014
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancerBharath Rudraraju, Marjolein Droog, Tarek M A Abdel-Fatah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb TrialHans Wildiers, Anne Armstrong, Eveline Cuypere, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 23, 2018
Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network studyAlessandra Franzetti Pellanda, Berardino De Bari, Elisabeth Deniaud-Alexandre, et al.
Nature|April 8, 2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancerJean E Abraham, Karen Pinilla, Alimu Dayimu, et al.
Nature Communications|May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trialJean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2012
Variation in telangiectasia predisposing genes is associated with overall radiation toxicityGeorge A Tanteles, Robert J S Murray, Jamie Mills, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2015
SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast CancerWilbert Zwart, Koen D Flach, Bharath Rudraraju, et al.
Breast Cancer Research and Treatment|August 22, 2014
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancerBharath Rudraraju, Marjolein Droog, Tarek M A Abdel-Fatah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb TrialHans Wildiers, Anne Armstrong, Eveline Cuypere, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 23, 2018
Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network studyAlessandra Franzetti Pellanda, Berardino De Bari, Elisabeth Deniaud-Alexandre, et al.
Nature|April 8, 2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancerJean E Abraham, Karen Pinilla, Alimu Dayimu, et al.
Nature Communications|May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trialJean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, et al.
Pageof 2